Mersana Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018	2017
Market Capitalization	382	280	585	447	1,823	274	95	374
Market Cap Growth	-	-52.15%	30.71%	-75.46%	564.32%	190.08%	-74.70%	-
Enterprise Value	207	104	340	308	1,584	182	24	259
PE Ratio	-1.63	-1.63	-2.86	-2.63	-20.70	-9.73	-1.47	-9.66
PS Ratio	10.37	7.59	22.00	10402.13	2201.35	6.51	8.93	21.31
PB Ratio	10.36	7.58	6.35	3.67	7.99	3.50	10.75	5.34
P/FCF Ratio	-1.64	-1.64	-11.34	-3.18	-24.25	-4.01	-1.67	-8.53
P/OCF Ratio	-1.66	-1.66	-11.84	-3.20	-24.40	-4.05	-1.71	-8.76
EV/Sales Ratio	5.61	2.83	12.80	7151.64	1913.28	4.33	2.31	14.77
EV/EBITDA Ratio	-0.64	-0.64	-1.73	-1.85	-18.28	-6.82	-0.39	-6.86
EV/EBIT Ratio	-0.62	-0.62	-1.69	-1.82	-18.07	-6.52	-0.38	-6.69
EV/FCF Ratio	-0.61	-0.61	-6.60	-2.19	-21.08	-2.67	-0.43	-5.91
Debt / Equity Ratio	0.91	0.91	0.39	0.31	0.07	0.10	-	-
Debt / EBITDA Ratio	-0.21	-0.21	-0.18	-0.23	-0.19	-0.29	-	-
Debt / FCF Ratio	-0.20	-0.20	-0.70	-0.27	-0.22	-0.11	-	-
Quick Ratio	3.29	3.29	3.39	3.74	8.50	4.15	1.02	3.62
Current Ratio	3.36	3.36	3.49	3.98	8.62	4.21	1.07	3.69
Asset Turnover	0.13	0.13	0.09	0	0.00	0.33	0.11	0.16
Interest Coverage	-41.15	-41.15	-60.36	-133.22	-244.25	-119.55	-	-
Return on Equity (ROE)	-282.40%	-282.40%	-178.80%	-101.40%	-43.10%	-27.90%	-182.40%	-829.30%
Return on Assets (ROA)	-62.60%	-62.60%	-70.40%	-73.50%	-36.30%	-21.80%	-65.00%	-34.10%
Return on Capital (ROIC)	-254.72%	-254.72%	-158.75%	-105.59%	-36.01%	-35.08%	-746.50%	-56.60%
Earnings Yield	-44.91%	-61.37%	-34.93%	-38.02%	-4.83%	-10.28%	-67.94%	-10.35%
FCF Yield	-44.75%	-61.14%	-8.82%	-31.44%	-4.12%	-24.91%	-59.83%	-11.72%
Buyback Yield / Dilution	-23.98%	-23.98%	-32.69%	-14.79%	-41.37%	-88.83%	-91.57%	-849.09%
Total Shareholder Return	-23.98%	-23.98%	-32.69%	-14.79%	-41.37%	-88.83%	-91.57%	-849.09%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).